B. Riley FBR: uniQure (NASDAQ:QURE) has $50 Target Has New Rating.

June 29, 2018 - By Maria Fierro

uniQure N.V. (NASDAQ:QURE) Corporate Logo

What Price Target Has B. Riley FBR Given uniQure (NASDAQ:QURE)

The financial firm B. Riley FBR has initiated coverage of QURE’s shares on 28 June. B. Riley FBR’s Analysts have has “Buy” rating while setting the TP at $50.

uniQure N.V. (NASDAQ:QURE) Ratings Coverage

Total analysts of 7 have positions in uniQure NV (NASDAQ:QURE) as follows: 7 rated it a “Buy”, 0 with “Sell” and 0 with “Hold”. The positive are 100%. Since January 3, 2018 according to StockzIntelligence Inc uniQure NV has 8 analyst reports. On Thursday, March 15 the firm has “Buy” rating by H.C. Wainwright given. In Wednesday, May 23 report Chardan Capital Markets maintained it with “Buy” rating and $5000 target. On Wednesday, January 3 the stock has “Buy” rating by Janney Capital. In Monday, May 7 report Leerink Swann maintained it with “Buy” rating and $6300 target. On Tuesday, March 20 Janney Capital maintained uniQure N.V. (NASDAQ:QURE) with “Buy” rating. On Wednesday, May 16 the rating was initiated by Wells Fargo with “Buy”.

QURE reached $37.69 during the last trading session after $0.86 change.uniQure N.V. has volume of 98,076 shares. Since June 29, 2017 QURE has risen 534.87% and is uptrending. The stock outperformed the S&P 500 by 522.30%.

uniQure N.V. (NASDAQ:QURE)’s earnings release is awaited by WallStreet on August, 14, Zacks reports. Last year’s EPS was $-0.83, while now analysts expect change of 22.89 % up from current $-0.64 EPS. Last quarter $-0.59 EPS was reported. Analysts sees 8.47 % negative EPS growth this quarter.

uniQure N.V., a gene therapy company, engages in the discovery, development, and commercialization of gene therapies in the Netherlands.The firm is valued at $1.40 billion. The firm develops AMT-060, which is in Phase I/II clinical trial to treat hemophilia B; AMT-061, a gene therapy that is in Phase III clinical trial for the treatment of hemophilia; and AMT-126, a gene therapy for the treatment of congestive heart failure and AMT-130 to treat huntington's disease.Last it reported negative earnings.

For more uniQure N.V. (NASDAQ:QURE) news brought out recently go to: Nasdaq.com, Streetinsider.com, Benzinga.com, Benzinga.com or Benzinga.com. The titles are as follows: “Analysis: Positioning to Benefit within Willis Towers Watson Public, MyoKardia, Texas Capital Bancshares, uniQure NV …” brought out on June 06, 2018, “uniQure (QURE) Appoints Robert Gut, MD, Ph.D. and David Meek to Board” on June 13, 2018, “3 Reasons Why Uniqure Could Overtake Hemophilia B Virus Gene Therapy” with a publish date: June 28, 2018, “AMT 061” and the last “Benzinga’s Daily Biotech Pulse: AbbVie Launches New Pediatric Humira, IPO Deluge Hits The Street” with publication date: June 21, 2018.

uniQure N.V. (NASDAQ:QURE) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.